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Abstract
This comment discusses the requirements, challenges and limitations for setting up medical device registries for
breast implants. Previous experiences, notably the PIP implant scandal in 2010, revealed the inaccuracy and
inefficiency of the majority of breast registers in place, and resulted in a rethinking of how registries should work.
Quality registries monitor the three Ps: person (eg. patient, surgeon), part (eg. device) and place (eg. hospital).
Setting up a register requires a minimum agreed dataset and clearly defined endpoints (eg. revision) of a
permanently implanted medical device (eg. breast implant) by means of a medical intervention (operation) readily
recorded in a routine procedure, where a direct causal and logical relationship between the malfunction of the
device and revision operation exist. Apart from the technical realization, the hurdles for setting up a registry are
predominantly found in the political, ethical, financial, and governing spheres. The possible benefits of a working
registry for the stakeholders might be evident, and include a market overview (industry), recall mechanism
(surgeons, industry, and patients), benchmarking (surgeons, hospitals) legal, quality management (governing body),
(eg. national vs. international) of and participation (opt-in vs. opt-out) in a given registry. Future efforts should take
into account past experiences and build upon international collaborations to develop optimal solutions for improving
patient safety.
Keywords: Implant registry, Implant register, Medical device, Regulation, Legislation, Recall, Plastic surgery,
Patient-reported outcome, Radiofrequency identification tags, RFIDBackground
The global medical aesthetic devices market was valued
at USD 1.8 billion (US dollars) in 2009 and is forecast to
reach USD 2.9 billion in 2016. The largest share is at-
tributed to breast implants, of which the market valued
at USD 936.5 million in 2013 and is forecast with a com-
pounded annual growth rate of 6.08 percent for the
period 2013–2018 [1,2].
Breast implants are classified as high-risk medical de-
vices. In 2013, 290224 breast augmentations with breast
implants (+1% vs. 2012), 23770 implant removals (aug-
mentation only) (+10% vs. 2012), as well as 95589
breast reconstructions (+4% vs. 2012), 18 223 implant
removals (reconstruction only) (+10% vs. 2012) were
performed in the United States. The data were obtained* Correspondence: david.lumenta@gmail.com
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creativecommons.org/publicdomain/zero/1.0/from a questionnaire distributed to 23700 American
Board of Medical Specialties certified Physicians/Surgeons,
of which a total of 801 active physicians returned the
questionnaire. Survey results were combined with the
Tracking Operations and Outcomes for Plastic Surgeons
database, responses aggregated and extrapolated to the
entire population of more than 24500 board certified phy-
sicians most likely to perform cosmetic and reconstructive
plastic surgery procedures [3]. These numbers do not
include so-called "out-of-spectrum" procedures by non-
board certified clinicians performing cosmetic surgery [4].
The methodology to retrieve data on breast implants
is, however, not solidly evidence-based, and it is striking
that there are currently no instruments available to ac-
curately measure their outcome after implantation. For
example, when performing a PubMed search (last per-
formed on 30 December 2014) with the terms "implant
register" and "implant registry" only 4.7% (19/404) and
9.4% (61/648) contained the word "breast", respectively.Access article distributed under the terms of the Creative Commons Attribution
by/4.0), which permits unrestricted use, distribution, and reproduction in any
ly credited. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
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in the context of breast implants, which cannot be
reliably answered due to scarce evidence available.
List of questions
 What is the recommended in-vivo lifespan of a
breast implant?
 How effective are antibiotics in reducing capsular
contracture?
 How many PIP implants were inserted until 2010?
The so-called Poly Implant Prothèse (PIP) crisis in 2010,
where low-grade industrial silicone was used for implants
with a higher than normal rupture rate, highlighted the
problem of recall by Institutions alone, and underlined me-
dia’s beneficial effect in improving recall [5]. The Australian
breast implant registry revealed that less than 4% of these
implants were captured in an opt-in (voluntary type of data
entry), triggering a revision of the system [6].
A lesson learned from major global breast implant crisis
in 2010 was the need to improve patient safety and patient
traceability.Table 1 Stakeholders
Stakeholders Benefits Prerequisite
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Government Patient safety, regulatory
instrument
Legislative framework,
data protectionRealism vs. idealism
Ideally, registries collect variables for risk adjustment,
indicators to assess quality of care, and finally out-
come data by using an opt-out system to achieve a
high-capture rate, which allows benchmarking of
current complication and revision rates and evaluate
concerns about implant composition, defects or dis-
ease associations verified with access to a large dataset.
Outcome registers monitor specific endpoints, which
can be readily recorded by the consequence relevant for
monitoring a complication [7]: in implants this is revision
surgery for managing that complication, which can be di-
vided into for example, wound revision, implant removal
or exchange. Quality registries expand on this and aim to
monitor the three Ps: person (eg. patient, surgeon), part
(eg. device) and place (eg. hospital).
The data collected need to be based on a minimum
data set, comparable to an universal industry standard
(as seen with SD cards in the information technology
sector), which allows comparing of data ("like with
like"). Data definitions should be simple and concise,
and industry should support a unique ID system
across all manufacturers. Outcome needs to be clearly
defined and recordable in routine clinical settings.
Prerequisites for installment of outcome registries are
in the List of Prerequisites for installment of an out-
come registry. Problems with data security concerns
could be overcome by linking unique identifier
implant IDs to the registry without revealing actual
personal data of patients.Prerequisites for installment of an outcome
registry*
 Permanently-implanted medical device that can
only be removed, exchanged or repaired by means
of a medical intervention (=revision).
 Causal and logical relationship between a malfunction
(of the implanted medical device) anda medical
intervention for its correction (revision).
 Implant failure leads to an intervention
(=endpoint), which is readily documented in a
routine procedure.
*Adapted from EAR-EFORT (European Arthroplasty
Register - European Federation of National
Associations of Orthopaedics and Traumatology).
Stakeholders (Table 1) in the market traditionally
share a hesitant approach towards ubiquitous control.
Governmental incentives for developing an implant
registry strongly depend on legislative priorities and
financial considerations especially in strained eco-
nomic times. On the one hand, industry stakeholders
are interested in an actual market share overview. On
the other hand, surgeons could benchmark their
implant-revision performance, and patients were finally
able to participate in an automobile industry-grade re-
call system following self-triggered registration. With
varying degrees of interest present and notably lobbying
groups focusing on respective advantages, it seems
difficult to create a registry just out of volun-
tary participation (e.g., by medical societies, "bottom-
up-approach"). Past experiences have revealed that a pure
voluntary involvement for the participation in a registry
(opt-in) produced an insufficient dataset (re: PIP crisis).
Governmental legislation giving the registry the option
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ising ("top-down-approach"). This so-called "independent
body" could be a nominated trustworthy institution, for
example a university, a specialist department or a dedi-
cated data collection agency with expertise in large epi-
demiological data. The term "opt-out" refers to the
way, in which agreement for inclusion into a registry
database works and differs from informed consent
(e.g., for a medical intervention). It is actually an insti-
tutional permission to allow all doctors and patients
to automatically enroll onto a registry, with appropri-
ate explanation via an explanatory statement, unless
they opt-out.
Several challenges (see List of Challenges) exist not
just among the stakeholders, but also in the lobbying
groups themselves. Breast implants are not just used
by one single surgical specialty, and differing interests
by respective medical societies might hinder collective
action towards the development of a single national
registry. Negative sentiment and suspicion might also
derive from surgeons themselves irrelevant of their
organizational representation, particularly when there
is more than one group involved performing opera-
tions with breast implants. A common problem dis-
couraging clinician participation was the complexity
of data collection forms trying to capture as much in-
formation as possible, varying by surgical specialty,
instead of a "less is more"-approach; less primary data
requests will generate more compliance and therefore
a higher capture rate and ultimately more data. Add-
itionally, the transfer of, for example, European law
into national legislation within the European Union
might prove challenging due to differing interpreta-
tions of data protection and its implementation. In
this context, the sharing of data on an international
level needs to consider ownership issues. Central to
the development of a functioning registry is the trust
of every stakeholder in the independence of its board,
which can be accomplished by access of each lobby-
ing group to the governing board with periodical ro-
tations in its management. While the security of
servers and solidity of data entry is key, so is the
regular maintenance and review of data, requiring im-
plementation of alarm triggers to identify underper-
formance or even risks for patients at an early stage.
Clearly defined outcomes should ideally be more than
the revision endpoint itself, because there may be pa-
tients with implants with bad outcomes, who have
not had a revision, and this could be included by the
use of patient-reported outcomes as well as specific
triggers for revisionary surgery going beyond the pure
malfunctioning of a medical device (eg. capsular
contracture causing a breast deformity by the tissue
surrounding an implant).List of challenges
 Negative sentiment from clinicians.
 Collaboration among specalties.
 Ethical approval.
 Consent processes.










 Registry costs.Learn from the past, be ready for the future
A purely technical focus of a medical device does not
suffice to evaluate outcomes in medicine, it is there-
fore necessary to include medical parameters and
patient-reported data as a requirement to receive a
“whole picture” of evidence for the future analysis of
breast implants. Unique identifiers for devices (from
industry) and interventions (from surgeons) without
revealing personal data could become more than just
read-only transducers and stakeholders could profit
from it as a dynamic monitoring tool. The challenges
faced by medical tourism will demand cooperation
going beyond national initiatives and all stakeholders
could benefit from international collaborations. This
drive has already spawned international initiatives
among national plastic surgery societies, national
health services and national health regulatory agencies
[8]. This leading role is inherent to plastic surgeons
as representatives of the specialty predominantly in-
volved in and associated with the use of breast im-
plants, but requires to recruit other groups of
clinicians to shoulder the efforts in developing orderly
standards of care and quality for the patients' benefit.
The new frontier incorporates patient-reported out-
comes along with information technology triggered
developments like radiofrequency identification tags
to innovate the generation of truly objective data.
This will facilitate the production of automated
reporting from intelligent data mining to anticipate
future trends of breast implants, be it sales, improved
outcomes or even adverse reactions. Future efforts
should take into account the past experiences made,
create innovative incentives (see List of Incentives),
and build upon international collaborations to develop
optimal solutions for ultimately improving patient
safety.
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List of incentives
 Opt-out (mandatory data entry).
 Electronic implant ID (linked to registry).
 Product recall triggered by industry/surgeons/
government with automated notifications to patients.
 Integration of patient-reported outcomes.
 Innovative product concepts (e.g., radio frequency
identification tags).
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
DBL and RC 1) have made substantial contributions to conception and
design, or acquisition of data, or analysis and interpretation of data; 2) have
been involved in drafting the manuscript or revising it critically for important
intellectual content; 3) have given final approval of the version to be
published; and 4) agree to be accountable for all aspects of the work in
ensuring that questions related to the accuracy or integrity of any part of
the work are appropriately investigated and resolved. Both authors read and
approved the final manuscript.
Author details
1Division of Plastic, Aesthetic and Reconstructive Surgery, Department of
Surgery, Consultant Plastic Surgeon, Assistant Professor, Medical University of
Graz, Auenbruggerplatz 29, Graz 8036, Austria. 2Department of Epidemiology
and Preventive Medicine, Clinical Professor, Monash University, Melbourne,
Australia. 3Plastic Surgeon, Waverley House Plastic Surgery Centre, Adelaide,
South Australia, Australia.
Received: 2 January 2015 Accepted: 28 January 2015
References
1. Global Breast Implants Market 2014–2018. [http://www.researchandmarkets.com/
research/zzzbzp/global_breast]
2. TechNavio: Silicone Breast Implants account for 77 percent of the Global
Breast Implants Market: TechNavio Report. 2013.
3. ASPS: 2013 Plastic Surgery Statistics Report. ASPS Public Relations, American
Society of Plastic Surgeons, USA; 2013.
4. Barr JS, Sinno S, Cimino M, Saadeh PB: Clinicians performing cosmetic
surgery in the community: a nationwide analysis of physician
certification. Plast Reconstr Surg 2015, 135:92e–98e.
5. Berry MG, Stanek JJ: PIP implant biodurability: a post-publicity update.
J Plast Reconstr Aesthet Surg 2013, 66:1174–1181.
6. Jeeves AE, Cooter RD: Transforming Australia's Breast Implant Registry.
Med J Aust 2012, 196:232–234.
7. Dindo D, Demartines N, Clavien PA: Classification of surgical
complications: a new proposal with evaluation in a cohort of 6336
patients and results of a survey. Ann Surg 2004, 240:205–213.
8. Cooter RD, Barker S, Carroll SM, Evans GR, von Fritschen U, Hoflehner H, Le
Louarn C, Lumenta DB, Mathijssen IM, McNeil J, Mulgrew S, Mureau MA,
Perks G, Rakhorst H, Randquist C, Topaz M, Verheyden C, de Waal J:
International Importance of robust breast device registries. Plast Rekonstr
Surg 2015, 135:330–336.
doi:10.1186/2056-5917-1-4
Cite this article as: Lumenta and Cooter: Medical device registries for
breast implants - where to? Safety in Health 2015 1:4.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
